Dr. Usmani, MD, MBA, FACP provides insights into Selinexor's safety profile in Relapsed/Refractory Multiple Myeloma (R/R MM), comparing it with other treatments and delve into the ongoing challenges and unmet needs in R/R MM patient care.
Alissa Cooper, MD, reviews new data for established and emerging antibody-drug conjugate targets in non–small cell lung cancer and argues that payload innovation and better patient selection are the field's greatest needs.